Recent Updates in the Treatment of Chronic Lymphocytic Leukemia: Year in Review 2022 - Episode 3

BTK Inhibitors for the Treatment of Relapsed CLL

, , ,

Seema Ali Bhat, MD, explains the SEQUOIA trial and the BTK inhibitor zanubrutinib for the frontline treatment of CLL, and Alexey Danilov, MD, PhD, describes the ASCEND trial that led to the approval of acalabrutinib for relapsed CLL.